Nitric oxide (NO), a reactive diatomic gas and a potent signaling molecule, is required for proper cardiovascular functioning. Soluble guanylate cyclase (sGC), a heterodimeric heme protein, is the key intracellular NO receptor protein which, upon NO binding, undergoes conformational changes leading to catalysis and the cGMP signaling cascade. Several small molecules that allosterically stimulate sGC have been developed for treatment of pulmonary hypertension, but little is known about their binding site or how they stimulate activity. This dissertation describes experiments designed to uncover the molecular basis for signal transduction in sGC by NO and small molecule stimulators. The crystal structure of the α-subunit PAS domain from Manduca sexta (Ms) sGC was solved at 1.8 Å resolution revealing the expected PAS fold but with an additional β strand and a shorter Fα helix. CO binding measurements on different Ms sGC N-terminal constructs and the β₁ (1-380) construct revealed that the α-subunit keeps the β₁ H-NOX domain in an inhibited conformation and this inhibition is relieved by removal of the α-subunit or by addition of stimulatory compounds such as compound YC-1. Linked-equilibria measurements on the N-terminal constructs show that YC-1 binding affinity is increased in the presence of CO. Surface plasmon resonance (SPR) studies on the in-vitro biotinylated constructs showed that YC-1 binds near or directly to the β₁ H-NOX domain. Computational and mutational analysis of the β₁ H-NOX domain revealed a pocket important in allostery and drug action. Finally, we show that the coiled coil domain plays an important role in allosteric regulation of the β₁ H-NOX domain and possibly in signal transduction. Our data are consistent with a model of allosteric activation in which the α-subunit and the coiled coil domains function to keep heme in a low affinity conformation while YC-1 binding to the β₁ H-NOX domain switches heme to a high affinity conformation, and sGC to its high activity form.

In this thesis, I present a model of multidomain evolution with associated algorithms and software for phylogenetic analysis of multidomain families, as well as applications of this novel methodology to case-studies and the human genome. Phylogenetic analysis is of central importance to understanding the origins and evolution of life on earth. In biomedical research, molecular phylogenetics has proved an essential tool for practical applications. Current molecular phylogenetic methods are not equipped, however, to model many of the unique characteristics of multidomain families. Genes that encode this large and important class of proteins are characterized by a mosaic of sequence fragments that encode structural or functional modules, called domains. Multidomain families evolve via domain shuffling, a process that includes insertion, internal duplication, and deletion of domains. This versatile evolutionary mechanism played a transformative role in major evolutionary transitions, including the emergence of multicellular animals and the vertebrate immune system. Multidomain families are ill-suited to current methods for phylogeny reconstruction due to their mosaic composition. Different regions of the same protein may have different evolutionary histories. Moreover, a protein may contain domains that also occur in otherwise unrelated proteins. These attributes pose substantial obstacles for phylogenetic methods that require a multiple sequence alignment as input. In addition, current methods do not incorporate a model of domain shuffling and hence, cannot infer the events that occurred in the history of the family. I address this problem by treating a multidomain family as a set of co-evolving domains, each with its own history. If the family is evolving by vertical descent from a conserved set of ancestral domains, then all constituent domains will have the same phylogenetic history. Disagreement between domain tree topologies is evidence that the family evolved through processes other than speciation and gene duplication. My algorithms exploit this information to reconstruct the history of domain shuffling in the family, as well as the timing of these events and the ancestral domain composition. I have implemented these algorithms in software that outputs the most parsimonious history of events for each domain family. The software also reconstructs a composite family history, including duplications, insertions and losses of all constituent domains and ancestral domain composition. My approach is capable of more detailed and accurate reconstructions than the widely used domain architecture model, which ignores sequence variation between domain instances. In contrast, my approach is based on an explicit model of events and captures sequence variation between domain instances. I demonstrate the utility of this method through case studies of notch-related proteins, protein tyrosine kinases, and membrane-associated guanylate kinases. I further present a largescale analysis of domain shuffling processes through comparison of all pairs of domain families that co-occur in a protein in the human genome. These analyses suggest that (1) a remarkably greater amount of domain shuffling may have occurred than previously thought and (2) that it is not uncommon for the same domain architecture to arise more than once through independent events. This stands in contrast to earlier reports that convergent evolution of domain architecture is rare and suggests that incorporating sequence variation in evolutionary analyses of multidomain families is a crucial requirement for accurate inference.

<p>Guanylate binding proteins (Gbps) are a family of large GTPases that are highly stimulated by IFNγ and confer resistance to various viral, protozoan, and bacterial pathogens. Following infections of intracellular pathogens, multiple Gbps can localize to pathogen vacuoles and promote the vesiculation and destruction of these structures. While Gbps have also been implicated in pathways independent of vacuolar disruption, their roles in these processes have been less characterized. In this dissertation, I focus on the mechanism of Gbps downstream of vacuolar disruption in order to further elucidate the role of these proteins during immune responses. </p><p> Due to the IFNγ stimulation of caspase-11 pyroptosis, I first addressed the ability of Gbps to promote the non-canonical caspase-11 dependent pathway of pyroptosis. I found that Gbpchr3-/- cells had reduced cell death in response to the vacuolar pathogen, L. pneumophila, and various LPS ligands. Using YFP-Gal3 as a marker for damaged membranes, I showed that there were equivalent levels of damaged pathogen vacuoles between WT and Gbpchr3-/- cells suggesting these proteins promoted pyroptosis independently of vacuolar disruption. Instead, it appears that Gbps modulate the activation of caspase-11 following LPS release into the cytosol. </p><p> The recruitment of Gbps is mediated by multiple host proteins including the Immunity Related GTPases and the autophagy conjugation system. I found in the second study that at least one Gbp, Gbp2, was also recruited to damaged vacuoles through the aid of Galectin-3, a β-galactoside binding protein, as well as the autophagy adaptor protein, p62. As all three proteins were also recruited to sterile damaged vesicles created by hypotonic shock, calcium phosphate precipitates, and lysosomal damage, it suggests Gbps are recruited through a universal mechanism which is independent of PAMP recognition. Interactions between p62, Gbp2, and Gal3 present a model whereby p62 facilitates the recruitment of Gbp2 to damaged membranes through interactions with Galectin-3. Their localization to these sites may subsequently facilitate autophagic degradation of membranes or promote the recruitment of pyroptotic complexes to modulate immune functions although this remains to be elucidated. </p><p> This dissertation examines the less characterized roles of Gbps downstream of vacuolar disruption. By uncovering these alternative pathways, this work provides a foundation to study the variations within the Gbp family and allows for the field to further understand the mechanisms by which they promote cellular immune responses.</p> / Dissertation

CoordenaÃÃo de AperfeiÃoamento de Pessoal de NÃvel Superior / A guanilina e a uroguanilina foram recentemente descobertas, respectivamente, no intestino e na urina, (Currie et al., 1992; Hamra et al., 1993). Fazem parte da famÃlia de peptÃdeos que ativam a guanilato ciclase de membrana (GC-C), aumentando os nÃveis intracelulares de cGMP (Schulz et al., 1990). EstÃo presentes em diversos tecidos, como respiratÃrio, linfonodos, testÃculos, cÃrebro e medula adrenal (Field et a.l., 1978; Forte et al., 1988, 1989; Hamra et al., 1993; Schulz et al., 1992). Foi comprovado que adicionando uma lisina na porÃÃo N-terminal, obtÃm-se um anÃlogo mais estÃvel e potente que a guanilina. O objetivo desse estudo à pesquisar os efeitos renais de um novo anÃlogo, ser-thr-lys-guanilina em sistema de perfusÃo. Os rins foram perfundidos com a soluÃÃo de Krebs-Henseleit modificada com 6g% de albumina bovina. Os dados foram comparados atravÃs de teste t de Student e ANOVA, com significÃncia p<0,05. Na dose de 0,1 Âg/mL, esse peptÃdeo apresentou efeitos similares aos da uroguanilina, na dose de 0,5 Âg/mL, em todos os parÃmetros testados. Ambas causaram aumento na pressÃo de perfusÃo (PP: de 101,5Â3,7 para 111Â2,9mmHg; de 101,2Â2,6 para 113,4Â2,5mmHg), no fluxo urinÃrio (FU: de 0,158Â0,016 para 0,223Â0,01 mL.g-1.min-1; de 0,16Â0,016 para 0,226Â0,2mL.g-1.min-1) e diminuiÃÃo no transporte tubular total e proximal de sÃdio (%TNa+: de 0,774Â0,06 para 0,724Â0,035; de 0,735Â0,065 para 0,773Â0,084), potÃssio (%TK+: de 66,89Â2,77 para 47,29Â3,34; de 63,54Â3,82 para 42,54Â8,14) e cloreto (%TCl-: de 85,69Â1,19 para 73,59Â2,63). Esses resultados foram similares aos previamente descritos apÃs a administraÃÃo da toxina termo-estÃvel da Escherichia coli (STa), guanilina, uroguanilina e lys-guanilina no mesmo sistema (Lima et al., 1992; Fonteles et al., 1996 e 1998). A dose maior (1 Âg/mL) causou aÃÃo antidiurÃtica (FU: de 0,165Â0,004 para 0,111Â0,009mL.g-1.min-1) e nenhum efeito sobre o transporte de sÃdio, embora a diminuiÃÃo na reabsorÃÃo tubular de potÃssio (%TK+: de 72,29Â1,2 para 49,73Â6,75) e cloreto (%TCl-: de 85,96Â0,79 para 81,9Â1,47) continuassem presentes. Nesta dose, nÃo apenas bloqueou o efeito diurÃtico da uroguanilina, como continuou causando um efeito antidiurÃtico significativo (FU: de 0,168Â0,004 para 0,116Â0,006). No entanto, nÃo foi capaz de bloquear os efeitos natriurÃticos da uroguanilina (%TNa+: de 85,35Â2,55 para 79,92Â1,05). O mecanismo de aÃÃo renal preciso dos peptÃdeos da famÃlia das guanilinas ainda nÃo foi completamente esclarecido. Sabe-se que esses peptÃdeos se ligam aos receptores GC-C (Schulz et al., 1990), porÃm hà indÃcios de que existam outras vias de aÃÃo renal, independentes desse receptor. Hà ainda a possibilidade de que haja duas entidades agindo de modo antagÃnico no sistema. Talvez haja a necessidade de isolÃ-los. A descoberta dos peptÃdeos da famÃlia das guanilinas promoveu avanÃos significativos na compreensÃo da regulaÃÃo endÃgena dos transportes de Ãgua e eletrÃlitos. O completo esclarecimento do seu mecanismo de aÃÃo renal oferece perspectivas reais para o tratamento de doenÃas como a hipertensÃo arterial. / Guanylin and uroguanylin are members of a family of peptides that stimulates cGMP production in several organic tissues, as intestine, kidney, airway, linfonodes, testis, brain and adrenal medulla (Field et a.l., 1978; Forte et al., 1988, 1989; Hamra et al., 1993; Schulz et al., 1992). Their 15 amino acid structures have been identified from rat intestine and opossum urine, respectively (Currie et al., 1992; Hamra et al., 1993), and they seem to be the link between intestine and kidney functions in controling blood pressure, as the âintestinal natriuretic hormoneâ suggested by some authors (Carey, 1978; Lennane et al., 1975). It was demonstrated that a Lysine-1 analog of guanylin is a more potent natriuretic and kaliuretic peptide. The aim of this study was to evaluate the renal effects of a novel analog of guanylin: ser-thr-lys-guanylin. Its effects were examined using isolated perfused kidneys from Wistar rats. All experiments were preceded by a 30 minutes internal control period and an external control group (C), in which the kidneys were perfused only with Krebs-Henseleit solution containing 6g% of a previously dialysed bovine albumine serum. The data was analyzed by Student t-test and ANOVA. The level of significance was set at p<0,05. Ser-thr-lys-guanylin, at the lowest dose (0.1 Âg/mL) and uroguanylin (0.5Âg/mL) caused similar effects. Both groups were able to increase perfusion presure (PP: 101.5Â3.7 to 111Â2.9mmHg; 101.2Â2.6 to 113.4Â2.5 mmHg), urinary flow (UF: 0.158Â0.016 to 0.223Â0.019 mL.g-1.min-1; 0.16Â0.016 to 0.226Â0.2mL.g-1.min-1) and to decrease sodium (%TNa+: 0.774Â0.06 to 0.724Â0.035; 0.735Â0.065 to 0.773Â0.084), potassium (%TK+: 66.89Â2.77 to 47.29Â3.34; 63.54Â3.82 to 42.54Â8.14) and cloride (%TCl-: 85.69Â1.19 to 73.59Â2.63) tubular reabsorption. Similar effects were also found in response to the Escherichia coli heat-stable enterotoxin (STa), guanylin, uroguanylin and lys-guanylin in the same system (Lima et al., 1992; Fonteles et al., 1996 e 1998). However, a greater dose (1Âg/mL), not only caused signifcantly decrease in the urinary flow (UF: 0.165Â0.004 to 0.111Â0.009 mL.g-1.min-1), but was also able to block the diuretic effects of uroguanylin (UF: 0.168Â0.004 to 0.116Â0.006 mL.g-1.min-1), although it still decreased potassium (%TK+: 72.29Â1.2 to 49.73Â6.75) and cloride(%TCl-: 85.96Â0.79 to 81.9Â1.47) tubular reabsorption. The precise renal mecanism of action of this family of peptides has not yet been fully elucidated. Deletion of GC-C genes in transgenic mice reveals that intestinal fluid secretion responses to STa are completely lost (Schulz et al., 1997 & Mann et al., 1997), but the natriuretic responses to STa and uroguanylin are retained (Carrithers et al., 1999), suggesting that other receptors are envolved. There is a possibility that there are to peptides causing antagonic effects. Further isolation may be necessary. Further studies are required to elucidate the specific renal mechanism of action of this new peptide. The discovery of guanylin and its family has promoted significant advances in the understanding of endogenous control of salt, water and eletrolites. The study of its analogs in perfused rat kidneys could help in elucidating their specific renal mecanism of action and bring great perspectives in the control of blood pressure.

Francisella tularensis, l'agent de la tularémie, est une bactérie intracellulaire capable d'infecter un grand nombre de cellules dont les macrophages. Le système immunitaire inné cytosolique est capable de détecter la bactérie à différents stades de son cycle d'infection. Dans un premier temps, le macrophage détecte la bactérie cytosolique et produit de l'interféron de type I. Cet interféron induit l'expression de milliers de gènes. Le macrophage est ensuite capable de détecter l'ADN cytosolique de la bactérie via un récepteur spécifique AIM2. La liaison AIM2-ADN entraine la formation d'un complexe multi-protéique appelé inflammasome et se composant de AIM2-ASC-caspase-1. L'activation de ce complexe conduit à la maturation de la caspase-1. Caspase-1 permet la sécrétion de deux cytokines majeures antimicrobiennes : l'IL-1beta et l'IL-18. De plus, caspase-1 induit une mort programmée des cellules infectées appelée pyroptose. La sécrétion de cytokines et la pyroptose sont deux évènements majeurs pour lutter contre les pathogènes. Ma thèse a consisté à identifier le lien entre l'interféron et l'activation de l inflammasome AIM2 dans des macrophages infectés par la bactérie Francisella. En réalisant un crible a l'aide d'ARNs interférents, j'ai découvert que 2 protéines sont impliquées dans l'activation de cet inflammasome, les guanylate binding proteins 2 et 5 (GBP2 et GBP5). En collaboration avec l'équipe du Dr. Broz en Suisse, nous avons démontré que les GBPs étaient impliquées dans le contrôle de la réplication intracellulaire de Francisella et également dans la lyse de la bactérie permettant le relargage d'ADN et l'activation de l'inflammasome AIM2. Les GBPs sont induites par l'interféron de type I mais très majoritairement par l'interféron de type II (IFN- gamma). Nous avons mis en évidence que le contrôle de la réplication bactérienne est GB dépendant et inflammasome-dépendant en absence d'IFN- gamma mais qu'il devient totalement GB dépendant et inflammasome-indépendant dans des macrophages pré-stimulés avec de l'IFN- gamma. De plus, la mort des macrophages pré-stimulés avec de l'IFN- gamma et infectés par Francisella est également GBP-dépendante et inflammasome-indépendante. En prenant en compte tous ces résultats, nous concluons que les GBPs sont des protéines impliquées dans l'immunité des macrophages infectés par Francisella mais qu'elles ont un double rôle : d'une part celui d'induire l'activation de l'inflammasome (la pyroptose) sous le contrôle de l'interféron de type I et d'autre part, d'induire une mort cellulaire et la lyse des bactéries cytosoliques de manière indépendante de l'inflammasome sous le contrôle d'IFN- gamma. Nos résultats placent donc les GBPs comme les effecteurs majeurs de l'immunité cytosolique antibactérienne suite au traitement par l'IFN-gamma / Francisella tularensis is an intracellular bacterium, and the causative agent of tularemia, capable of infecting a large number of cells including macrophages. The innate cytosolic immune system is capable of detecting the bacterium at different stages of its infection cycle. Macrophages first detect the DNA of the cytosolic bacterium and produce type I interferon. Type I interferon subsequently induces the expression of thousands of genes. The macrophages then detect the cytosolic DNA of the bacterium via a cytosolic DNA sensor called AIM2. The AIM2-DNA binding results in the formation of a multi-protein complex called the AIM2 inflammasome composed of AIM2-ASC-caspase-1. Activation of this complex leads to the maturation of caspase-1. Caspase-1 activation leads to the secretion of two major antimicrobial cytokines, IL-1ß and IL-18. In addition, caspase-1 induces a programmed cell death termed pyroptosis. Cytokine secretion and pyroptosis are two major events in the control of pathogens. My PhD focused in identifying the link between interferon and activation of the AIM2 inflammasome in macrophages infected with the pathogenic bacterium Francisella. I performed a RNA interference screening and identified two proteins involved in the activation of the AIM2 inflammasome: guanylate binding proteins 2 and 5 (GBP2 and GBP5). In collaboration with Dr. Broz’s team in Switzerland, we demonstrated that GBPs are involved in the control of intracellular replication of Francisella and also in the lysis of the bacterium allowing the release of bacterial DNA and the activation of inflammasome AIM2. GBPs are induced by type I interferon but to a much greater extent by type II interferon (IFN-gamma). In the second part of my work, we demonstrate that the control of bacterial replication is GBP-dependent and inflammasome-dependent in the absence of IFN-gamma but that it becomes fully GBP-dependent and inflammasome-independent in macrophages primed with IFN-gamma. Cell-death of macrophages primed with IFN-? and infected with Francisella is also GBP-dependent and inflammasome-independent. Taken together, these results demonstrate that GBPs are innate immunity proteins involved in the death of macrophages and the bacterial growth restriction through two differents pathways : one induces the activation of inflammasome (induction of Pyroptosis) controlled with type I interferon signaling and, another induces cell-death and bacterial killing in an inflammasome-independent manner under the control of IFN-gamma. Our results thus discriminates the antimicrobial action of the inflammasome and of GBPs and position GBPs as the master antibacterial effectors of IFN-gamma, a key cytokine to fight cytosolic bacteria

Πολλές παθήσεις του καρδιαγγειακού συστήματος σχετίζονται με την λειτουργία του ενζύμου της διαλυτής γουανυλικής κυκλάσης (soluble guanylate cyclase, sGC). Η sGC εμπλέκεται στο μονοπάτι ΝΟ-sGC-cGMP το οποίο ενεργοποιείται από το βιολογικά διαθέσιμο μονοξείδιο του αζώτου (nitric oxide, ΝΟ). Πολλές παθολογικές καταστάσεις αντιμετωπίστηκαν για πάνω από 140 χρόνια με τη χρήση φαρμάκων που παρέχουν NO (ΝΟ-φάρμακα), χωρίς ωστόσο να είναι γνωστός ο μηχανισμός δράσης τους. Αν και τα φάρμακα αυτά συνεισέφεραν στη βελτίωση των παθολογικών καταστάσεων, ωστόσο παρουσίαζαν σημαντικά μειονεκτήματα. Για την αντιμετώπιση αυτών, το ενδιαφέρον στράφηκε στον σχεδιασμό και την σύνθεση ενώσεων των οποίων η δράση θα ήταν ανεξάρτητη από το ΝΟ. Μεταξύ αυτών, τα παράγωγα BAY 58-2667 και η HMR 1766 αποδείχθηκαν ενεργοποιητές της sGC. Στα πλαίσια της παρούσας μελέτης, σχεδιάσθηκαν και συντέθηκαν έξι νέα βενζοφουρανικά ανάλογα του HMR-1766, σε μία προσπάθεια ανακάλυψης νέων ενώσεων, ενεργοποιητών της sGC με ενισχυμένη δραστικότητα και εκλεκτικότητα δράσης. Η προσέγγιση που ακολουθήθηκε για την σύνθεση των τελικών προϊόντων περιελάμβανε την ανοικοδόμηση του βενζοφουρανικού δακτυλίου από υποκατεστημένα παράγωγα σαλικυλικού οξέος και την μετέπειτα σύζευξη αυτού με κατάλληλους δομικούς λίθους για τον σχηματισμό μίας σουλφοναμιδικής και μίας αμιδικής πλευρικής αλυσίδας. Στα πλαίσια της μελέτης, διερευνήθηκαν και βελτιστοποιήθηκαν όλα τα συνθετικά στάδια για την παραλαβή των ενδιάμεσων και των τελικών προϊόντων. Η μελλοντική αποτίμηση της βιολογικής δράσης των νέων ενώσεων αναμένεται να διευκρινίσει αν οι ενώσεις αυτές είναι ικανές να δράσουν ως ενεργοποιητές της sGC, αλλά και αν μπορούν να αποτελέσουν χρήσιμα χημικά εργαλεία για την διευκρίνιση δομικών πληροφοριών του ενζύμου. Το δεύτερο τμήμα της παρούσας εργασίας, αφορά στον σχεδιασμό και την σύνθεση νέων αναλόγων του φυσικού προιόντος Hymenialdesine (HMD). Η HMD είναι ένα φυσικό προϊόν το οποίο έχει αποδειχθεί αναστολέας πολλών πρωτεϊνικών κινασών, όπως των κυκλινο-εξαρτώμενων κινασών (CDKs), η υπερλειτουργία των CDKs ενέχεται στην εμφάνιση παθολογικών καταστάσεων (καρκίνος, νευροεκφυλιστικές παθήσεις, διαβήτης). Στόχος της μελέτης ήταν ο σχεδιασμός και η διερεύνηση της σύνθεσης νέων σπειρανικών ινδολοαζεπινικών αναλόγων της HMD, με ενισχυμένη ανασταλτική και εκλεκτική δράση έναντι των CDKs. Για το σκοπό αυτό, μελετήθηκε η μετατροπή της 5-κετονομάδας της αζεπινο[3,4-b]ινδολο-1,5-διόνης σε ένα αμινο-υποκατεστημένο στερεογονικό κέντρο μέσω νουκλεόφιλης προσβολής της πρόδρομης χειρόμορφης t-βουτυλοσουλφινυλ-ιμίνης. Διερευνήθηκαν ποικίλες πειραματικές συνθήκες για τη βελτιστοποίηση σχηματισμού τόσο της ενδιάμεσης σουλφινυλ-ιμίνης, όσο και της υποκατάστασης αυτής. Τα συνθετικά αυτά στάδια θεωρούνται κρίσιμα και η βελτιστοποίηση τους απαραίτητη για την ομαλή εξέλιξη του συνθετικού σχήματος. Τα αποτελέσματα που καταγράφηκαν στα πλαίσια της μελέτης αναμένεται να συμβάλλουν ουσιαστικά στην επιτυχή ολοκλήρωση της σύνθεσης των νέων σπειρανικών αναλόγων της HMD. / Many cardiovascular diseases are connected with the activity of soluble guanylate cyclase (sGC). sGC is part of the NO-sGC-cGMP pathway, which is activated by the biologically available nitric oxide (NO). Many drugs that release NO (NO-drugs) have been used for more than 140 years. Although these drugs have contributed to the treatment of these diseases, they have presented some disadvantages. Thus, new compounds have been discovered whose activity is independent of NO. Compounds BAY 58-2667 and HMR-1766 belong to this new class of compounds and are characterized as sGC activators. In the first part of this study, six new benzofuran derivatives of HMR-1766 were designed and synthesized, aiming at the discovery of new compounds, activators of sGC with enhanced activity and selectivity against sGC. The synthetic approach involves the initial formation of benzofuran ring from substituted derivatives of salicylic acid and its coupling with selected building blocks. The optimazation of all synthetic steps for the synthesis of the intermediate and final products was also part of this study. The biological evaluation of the new compounds is expected to reveal their biological activity as sGC activators and/or their role as chemical tools for the structural elucidation of the enzyme. The second part of this study, concerns the design and synthesis of new derivatives of Hymenialdesine (HMD). HMD is a natural product with inhibitory activity against many protein kinases, such as cyclin-dependent kinases (CDKs). Hypeactivation of CDKs is implicated in pathological disorders such as cancer, neurodegenerative diseases and diabetes. The aim of the study was the synthesis of new spiro-indolazepino derivatives of HMD with potential enhanced inhibitory activity and selectivity against CDKs. The transformation of the 5-ketogroup of the azepino[3,4-b]indol-1,5-dione to a new amino-substituted stereogenic center by nucleophilic attack of the intermediate chiral tert-sulfinylimine was the key-step of the synthetic approach. The results of this study are expected to contribute substantially to the synthesis of new spiro HMD derivatives.

Orientador: Fabíola Taufic Monica Iglesias / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas / Made available in DSpace on 2018-08-23T16:27:39Z (GMT). No. of bitstreams: 1 Faria_WagnerMendes_M.pdf: 1252281 bytes, checksum: ad80513967190699e0001046decc7731 (MD5) Previous issue date: 2013 / Resumo: Duas classes de medicamentos denominadas estimuladores e ativadores da guanilato ciclase solúvel (GCs) foram desenvolvidas para uso terapêutico em situações patológicas onde há menor formação ou biodisponibilidade NO ou tolerância farmacológica. A GCs é uma enzima heterodímera, composta pelas subunidades alfa (?) e beta (?), nas quais há a presença do grupo prostético heme e que catalisa a conversão da guanosina trifosfato (GTP) em guanosina monofosfato cíclico (GMPc) pela ação do NO. Em situações patológicas o átomo de ferro pode encontrar-se na sua forma oxidada (Fe3+), diminuindo assim a resposta máxima do óxido nítrico (NO). A principal diferença entre os moduladores da GCs é que os ativadores (BAY 58-2667, HMR 1766, BAY 60-2770) atuam de maneira mais eficaz mesmo quando a enzima encontra-se no estado oxidado. O objetivo do presente trabalho foi caracterizar funcionalmente o relaxamento induzido pelo BAY 60-2770 em artéria pulmonar isolada de coelho. O BAY 60-2770 (0,0001-100 ?M) relaxou de maneira potente (10,1 ± 0.04) e eficaz (105 ± 0,9 %) a artéria pulmonar, sendo este efeito significativamente potencializado na presença dos inibidores da GCs (ODQ, 10 ?M, 4,9 vezes), da fosfodiesterase tipo 5 (tadalafil, 100 ?M, 5,6 vezes) ou da sintase de óxido nítrico (LNAME, 100 ?M, 3,0 vezes). A presença do sequestrador de NO, do doador de NO, da indometacina, do bloqueador do canal de potássio ou a remoção endotelial não interferiram no relaxamento induzido pelo BAY 60-2770. A fenilefrina (0,00001-3 mM) e a estimulação elétrica (4-16 Hz) produziram contração dependente da concentração e frequência, respectivamente. Na presença de tetrodotoxina (TTX, 1 ?M) e fentolamina (1 ?M) houve abolição da resposta contrátil a estimulação elétrica, mostrando a liberação neurogênica de catecolamina. Na presença de BAY 60-2770 co-incubado com ODQ uma redução significativa na contração induzida pela estimulação elétrica foi observada. Apesar desta mesma redução ter sido observada na presença do L-NAME, a mesma não foi estatisticamente significante em comparação aos anéis incubados somente com BAY 60-2770 (1 ?M). Nossos resultados mostraram que a oxidação do grupamento heme, a inibição da fosfodiesterase e a ausência do NO favoreceram a resposta relaxante do BAY 60-2770 / Abstract: Soluble guanylate cyclase (sGC) stimulators and activators have been developed for use in pathophysiological condition when NO formation or bioavailability are impaired or when NO tolerance gas developed. Soluble guanylate cyclase is a heterodimer enzyme composed by alpha (?) and beta (?) subunits and a prostetic heme group. Soluble guanylate cyclase converts guanosine triphosphate (GTP) into cyclic guanosine monophosphate (GMPc) after nitric oxide (NO) activaton. Under pathophysiological conditions heme can be oxidized (Fe3+), thus reduzing NO efficacy. The main difference between stimulators and activators (BAY 58-2667, BAY 60-2770 and HMR 1766) is that the latter class of drugs is more efficacious when heme is oxidized. The aim of the present study is to characterize the relaxation induced by BAY 60-2770 in isolated pulmonary artery from rabbit. BAY 60-2770 (0.0001-100 ?M) produced concentration dependent relaxation with potency and maxima response values of 10,1 ± 0.04 and 105 ± 0.9%, respectively. The inhibition of sGC (ODQ, 10 ?M) or phosphodiesterase type 5 (tadalafil, 100 ?M) or the nitric oxide synthase (L-NAME, 100 ?M) produced significantly leftward shifts by, approximately, 4.9, 5.4 and 3.0, respectively. The NO-scavenger, the NO-donor, the cyclooxygenase inhibition, the potassium channel blocker or endothelial removal did not interfere on the pharmacological parameters of BAY 60-2770. Phenylephrine (PE, 0.0001- 3 mM) and electrical field stimulation (EFS, 4-16 Hz) induced concentration and frequency dependent-contraction, respectively. Phentolamine (1 ?M) and tetrodotoxin (TTX, 1 ??) practically abolished EFS-induced contraction, showing the neurogenic source of catecholamines. Co-treatment with BAY 60-2770 with ODQ reduced significantly the EFS-induced contraction in comparison with BAY 60- 2770 (1 ?M) alone. Although we have observed a tendency of reduction in the amplitude of contraction when BAY 60-2770 was co-incubated with L-NAME, it was not statistically significant. Therefore, our results showed that the oxidation of heme group, the inhibition of phosphodiesterase and lower levels of NO favoured the relaxing response of BAY 60- 2770 in isolated rabbit pulmonary artery / Mestrado / Farmacologia / Mestre em Farmacologia

Soluble guanylyl/guanylate cyclase (sGC), the primary receptor for nitric oxide (NO), is a heme containing heterodimeric enzyme involved in numerous physiological events in animals. The small molecule YC-1 stimulates sGC, but the mechanism behind and the location of binding are unknown. I have developed a prokaryotic expression system for insect ( <italic>Manduca sexta</italic>) sGC. The recombinant holoenzyme, like its mammalian counterpart, is responsive to NO, CO and YC-1, displaying a 175-fold increase in activity on binding. Truncated constructs containing the N-terminal two-thirds of both subunits (msGC-NT) were designed to facilitate expression. With the highly pure material, we investigated NO and CO binding, reaction kinetics and regulation. Binding of NO to msGC-NT heme forms a six-coordinate intermediate followed by release of the proximal histidine to yield a five-coordinate nitrosyl complex. The conversion rate is insensitive to nucleotides, YC-1 and changes in NO concentration up to ~30 micromolar. In contrast, NO release from msGC-NT is biphasic in the absence of YC-1, while binding of YC-1 eliminates the fast phase but has little effect on the slower phase. CO binding to msGC-NT is also regulated by YC-1. The CO release rate is reduced by YC-1 while the on rate remains unchanged, which leads to an ~50-fold increase in binding affinity. YC-1 binding leads to a substantial geminate recombination of CO to msGC-NT upon photolysis. Our data are consistent with a model for allosteric activation in which (1) YC-1 binds away from the catalytic site and (2) sGC undergoes a conformational switch between two states of an open and a closed heme pocket. The final catalysis results from the integration of the influence of numerous allosteric effectors on the equilibrium between these two states.<italic>S </italic>-nitrosoglutathione (GSNO) exists <italic>in vivo </italic> and plays important roles in NO signaling. We have developed a model cell line, in which inducible NO synthase and human sGC genes were included. GSNO stimulation of sGC has been investigated using recombinant insect and human enzymes. GSNO can activate sGC as efficiently as gaseous NO, but apparently with a distinct mechanism. GSNO or endogenous NO could <italic>S </italic>-nitrosylate sGC, which might regulate the enzyme function.

Le polyomavirus humain BK (virus BK) établit une infection persistante asymptomatique dans les voies rénales de 80% de la population humaine. Chez les patients transplantés, la réactivation du virus BK est à l'origine de néphropathies et de cystites hémorragiques. L'augmentation des pathologies associées au virus BK en même temps que l'utilisation de traitements immunosuppresseurs de plus en plus puissants souligne un lien étroit entre la réponse immunitaire de l'hôte et la réactivation virale. Cependant la réponse immune à l'infection par le virus BK, en particulier le rôle des cytokines antivirales dans le contrôle de l'infection est peu documentée. Ici, nous avons étudié l'efficacité antivirale des interférons (IFN) sur la multiplication du virus BK. Nous avons testé les IFN-alpha, lambda et gamma sur la souche Dunlop du virus BK dans les cellules Véro et MRC 5. L'IFN-gamma inhibe de façon dose-dépendante la transcription virale de la région précoce et de la région tardive ainsi que l'expression de la protéine virale VP1. Un moindre effet antiviral a été observé avec l'IFN-alpha et l'IFN lambda. Ces résultats sont associés à une phosphorylation prolongée de STAT 1 avec l'IFN-gamma, non retrouvée avec l'IFN-alpha et lambda. La différence d'efficacité entre ces trois types d'IFN suggère que certaines protéines induites seulement par l'IFN-gamma ont un effet antiviral dans l'infection par le virus BK. L'analyse transcriptionnelle révèle neuf protéines qui pourraient être impliquées dans cet effet antiviral spécifique. Parmi elles, nous avons étudié l'effet antiviral de l'indoleamine 2,3-dioxygénase (IDO) et les protéines de liaison au guanylate (GBP ou guanylate binding protéines), GBP1 et GBP2, sur le virus BK. Nos résultats montrent que GBP1 et GBP2 mais pas IDO contribuent à l'activité antivirale de l'IFN-gamma sur le virus BK. Trouver le mécanisme d'action de ces protéines antivirales induites par l'IFN pourrait nous aider à développer une stratégie thérapeutique / The human polyomavirus BK (BK virus) establishes an asymptomatic persistent infection in the urinary tract of 80% of the human population. In transplant recipients, reactivation of the BK virus infection is the cause of nephropathy and hemorrhagic cystitis. Diseases associated with BK virus infections are increasing at the same time as potent immunosuppressive therapies are developing. This highlights the importance of components of the immune system in controlling viral reactivation. However, the immune response to the BK virus, particularly the role of antiviral cytokines in infection control, is poorly documented. Here, we investigated the antiviral efficacy of interferons (IFN) on the BK virus multiplication. We tested IFN-alpha, lambda and gamma on the Dunlop strain of BK virus in Vero cells and MRC 5 cells. Treatment with IFN-gamma inhibited the expression of the viral protein VP1 in a dose dependent manner and decreased the expression of the early and late viral transcripts. A weaker antiviral effect was observed with IFN-alpha and IFN-lambda. These results are associated with a prolonged STAT1 phosphorylation with IFN-gamma but not with IFN-alpha and lambda. The difference of efficacy between these three types of interferon suggests that some interferon induced proteins only produced by IFN-gamma had an antiviral effect on BK virus infection. Transcriptomic analysis reveals that nine proteins could be involved in this specific antiviral effect. Among them, we selected and investigated the antiviral effect of indoleamine 2,3-dioxygenase (IDO) and guanylate binding protein 1 and 2 (GBP1 and GBP2) on the BK virus. Our results suggest that GBP1 and GBP2 but not IDO contribute to the antiviral activity of IFN-gamma on the BK virus. Finding the action mechanism of these IFN gamma induced antiviral proteins could help to develop a therapeutic strategy

No presente trabalho avaliamos o potencial do BAY 41-2272 e sua via, como uma ferramenta para modulação da função dos linfócitos. Para isso, realizamos tratamentos farmacológicos com BAY 41-2272, avaliando a produção de citocinas e observamos que este fármaco, como ativador direto, não induz produção de IFN, IL-4 e IL-10 nos linfócitos. No entanto, o prétratamento por 24 horas com BAY 41-2272, com posterior ativação com PMA, mostrou que esta droga tem efeito inibitório na produção das citocinas. Em vista disto, avaliamos se este fármaco seria capaz de ativar estas células através da expressão de CD69. Vimos que por si só esta droga não foi capaz de aumentar a expressão de CD69, no entanto o pré-tratamento com BAY 41-2272 inibiu a ativação dos linfócitos T CD4. Assim, avaliamos se o fármaco seria capaz de inibir a expressão de fatores de transcrição FOXP3, RORT, Tbet e GATA3. Vimos que o BAY 41-2272 não induziu expressão desses fatores de transcrição e o pré-tratamento com este fármaco não alterou a expressão de FOXP3, RORT e GATA3, mas inibiu a expressão de Tbet quando comparado ao estimulado com PMA e Ionomicina sem o prétratamento. Observamos também que o pré-tratamento com BAY 41-2272 inibiu a linfoproliferação. Estes resultados sugerem que o BAY 41-2272 e sua via, têm um perfil inibitório sobre os linfócitos T CD4, e potencialmente podem ser utilizados como imunomodulador em pacientes com comprometimento do sistema imunológico e síndromes linfoproliferativas. / In this work, we evaluated the potential of BAY 41-2272 and its pathway as a tool for modulating lymphocyte function. For this, we performed pharmacological treatments with BAY 41-2272, evaluating the production of cytokines and observed that this drug, as a direct activator, does not induce production of IFN, IL-4 e IL-10. However, pre-treatment for 24 hours with BAY 41-2272 and subsequente activation with PMA showed that this drug has an inhibitory effect on cytokine production. Thus, we evaluated if this drug would be able to activate these cells through the CD69 expression. We saw that alone, BAY 41-2272 was not able to increase CD69 expression, however, pre-treatment inhibited activation of CD4 T lymphocytes. Then, we evaluated if this chemical compound would be able to inhibite the expression of transcription factors FOXP3, RORT, Tbet and GATA3. We have seen that BAY 41-2272 did not induce expression of these transcription factors and pretreatment with this drug did not alter expression of FOXP3, RORT and GATA3, but inhibited Tbet expression. We also observed that pre-treatment with BAY 41-2272 inhibited lymphoproliferation. These results suggest that BAY 41-2272 and its pathway have an inhibitory profile on CD4 T lymphocytes and can potentially be used as an immunomodulator in patients with impaired imune system and lymphoproliferative syndromes.